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mmol/liter; serum cholesterol, 5.95 mmol/liter; serum triglycer-
ides, 1.40 mmol/liter; serum potassium, 4 mmol/liter; serum
creatinine, 95 mmol/liter (1.1 mg/dl); creatinine clearance, 112
ml/min/1.73 m2 body surface; and 24-hour urine albumin excre-
tion, 245 mg. Urinalysis revealed no other abnormalities. An
electrocardiogram showed a Sokolow-Lyon voltage of 3.9 mV.
Doppler ultrasonographic examination of the heart disclosed
increased left-ventricular mass index (LVMI 5 141 g/m2) and
increased left-ventricular relative wall thickness (RWT 5 0.47);
parameters of diastolic and systolic function were within nor-
mal limits. Renal ultrasonography revealed normal-sized kid-
neys with no parenchymal abnormality. No other medical prob-
lems were identified.
The patient was asked to seek dietary counseling to reduce
his sodium chloride intake, and lisinopril (10 mg once daily)
was prescribed. Over the next three months, his blood pressureCASE PRESENTATIONS
remained about 150/100 mm Hg, and the urinary sodium excre-
Patient 1. A 42-year-old white man was referred to the Uni- tion ranged between 80 and 100 mmol/day. The lisinopril dose
versity Clinic of the University of Navarra for evaluation of was increased to 20 mg daily. Under this therapeutic regimen,
arterial hypertension. Three years earlier, the patient had been blood pressure fell to below 140/90 mm Hg during the next
told he had elevated blood pressure during an insurance medi- nine months. One year after the initial medical examination,
cal examination. No antihypertensive therapy was prescribed a cardiac echocardiogram revealed diminution of the left-ven-
during the intervening period. tricular mass index (133 g/m2) and the RWT (0.43), and nephe-
His father had had hypertension and had died of a noncar- lometric analysis of the urine revealed a 24-hour albumin excre-
diovascular cause at age 70. The patient had had two episodes tion of 80 mg.
of urinary tract infection, but a rapid-sequence pyelogram did Patient 2. A 52-year-old white woman was referred to the
not reveal any abnormalities. He suffered often from head- University Clinic of the University of Navarra for the evalua-
aches, but he had no palpitations, sweating, or orthostatic falls tion of recent-onset hypertension. She had been normotensive
in blood pressure. He had no additional cardiovascular risk one year earlier. She had a strong family history of cardiovascu-
factors: he had never smoked; glucose tolerance was normal; lar disease: Her father died at age 55 with hypertension and
and plasma cholesterol concentration was below 6.35 mmol/ a myocardial infarction, and her mother died at age 60 of
liter. hypertension and a cerebrovascular accident. The patient did
On presentation at the outpatient clinic, his blood pressure not smoke and drank alcohol only occasionally.
was 168/110 mm Hg, and the pulse rate was 74 beats/min and The patient described herself as a healthy, active individual
regular. The body mass index was 24 kg/m2. Physical examina- without medical complaints. She had never used oral contra-
tion showed evidence of an enlarged left ventricle and a grade ceptives or cardiovascular drugs. Hypercholesterolemia had
2/6 mid-systolic ejection murmur. No carotid or abdominal been detected during a routine medical examination; only di-
bruits were heard. Pulses in the extremities were normal. No etary treatment had been recommended.
edema was present. Neurologic examination was normal. Fun- Physical examination revealed a thin, well-developed, well-
duscopic examination revealed mild arteriolar narrowing and nourished female. The body mass index was 26 kg/m2. The
arteriovenous crossing changes. blood pressure was 159/100 mm Hg. Cardiac examination dis-
closed a normal PMI, and normal sounds were noted. The abdo-Laboratory evaluation revealed: fasting plasma glucose, 5.0
men was not remarkable; no abdominal bruit was audible. No
edema was evident in the extremities. Musculoskeletal and
neurologic examinations were within normal limits. FunduscopyPresentation of this Forum is made possible by grants from Astra
revealed normal eye grounds, except for some mild arteriolarPharmaceuticals; Merck & Co., Incorporated; Hoechst Marion Rous-
narrowing.sel, Incorporated; Dialysis Clinic, Incorporated; and R & D Labora-
tories, Incorporated. Laboratory studies revealed: fasting plasma glucose, 6.10
mmol/liter; serum cholesterol, 7.12 mmol/liter; high-density lipo-
Key words: growth hormone, left-ventricular hypertrophy, insulin re- protein cholesterol, 0.70 mmol/liter; low-density lipoprotein
sistance, nitric oxide, ACE inhibitors, microalbuminuria. cholesterol, 6.00 mmol/liter; and serum triglycerides, 2.10
mmol/liter. A complete blood count, as well as tests for serum 1999 by the International Society of Nephrology
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creatinine, uric acid, and electrolytes, were normal, as was In this Nephrology Forum, I will review the most
urinalysis. An electrocardiogram was normal. Ultrasound ex- prominent data on the biochemistry and biologic actions
aminations of the heart and kidneys were unrevealing. Fasting
of IGF-I, with a special focus on the physiologic effectsplasma insulin concentration was 25 mU/ml, above the upper
of the factor on the cardiovascular system. Also, I willnormal limit for normotensives in our laboratory (20 mU/ml).
The patient underwent an oral glucose tolerance test after address the evidence suggesting that alterations in the
ingestion of a drink containing 40 g glucose/m2 body surface. synthesis, secretion, and/or tissue bioavailability of
The two-hour glucose and insulin concentrations were above IGF-I participate in the pathophysiology of essential hy-
the upper limit of normal in controls (glucose, 7.8 mmol/liter;
pertension. Finally, I will propose that some of the bene-insulin, 50 mU/ml).
ficial effects produced by ACE inhibitors are related toThe patient began a sodium chloride- and fat-restricted diet,
and lisinopril (10 mg once daily) was prescribed. Over the their capacity to modify the production and/or the tissue
ensuing six months, her blood pressure was 146/95 mm Hg. bioavailability of IGF-I in hypertensive patients.
At that time, laboratory examination showed: fasting plasma
glucose, 5.50 mmol/liter; serum cholesterol, 6.95 mmol/liter; Biochemistry and physiology of IGF-I
serum triglycerides, 1.80 mmol/liter; and fasting plasma insulin,
Insulin-like growth factor I belongs to a family of sin-16 mU/ml. Pravastatin, a lipid-lowering drug, was begun, and
the lisinopril dose was increased to 20 mg once daily. After gle-chain polypeptides (IGF-I and IGF-II) with struc-
one year of treatment, her blood pressure was below 140/90 tural homology to proinsulin [4]. Insulin-like growth fac-
mm Hg, and the blood metabolic parameters were within nor- tor I consists of 70 amino acid residues with a predicted
mal limits, that is, glucose, 5.30 mmol/liter; cholesterol, 6 mmol/
molecular weight of 7649 Da; IGF-II consists of 67 aminoliter; triglycerides, 1.50 mmol/liter; and insulin, 14 mU/ml.
acids and has a predicted molecular weight of 7469 Da.
Comparison of the primary sequences of the IGFs allows
recognition of B, C, and A domains, as in pro-insulin.
In addition, the IGFs have a carboxy-terminal extension
DISCUSSION (D domain) not present in pro-insulin. Insulin-like growth
factors are 70% identical to one another, and their ADr. Javier Di´ez (Professor of Medicine and Director,
and B domains are 50% identical to the A and B chainsVascular Pathophysiology Unit, School of Medicine, Uni-
of human insulin.versity of Navarra, Pamplona, and Professor of Medicine,
The human IGF-I gene has been mapped to the longSchool of Medicine, University of Zaragoza, Zaragoza,
arm of chromosome 12 [5]. It comprises at least fiveSpain): These two patients illustrate some of the most
exons spread over more than 90 kbp. The gene encodesrelevant pathophysiologic features of essential hyperten-
two precursor forms of IGF-I, represented by transcriptssion. The first patient exhibited cardiac and renal dam-
with distinct 39 regions. The resulting precursor formsage, as evidenced by the presence of concentric left-
of IGF-Ia and IGF-Ib differ in the terminal portion ofventricular hypertrophy (LVH) and microalbuminuria,
their carboxy-terminal peptides. Regulation of IGF-Irespectively. The second patient had one of the meta-
gene expression can occur at several sites, namely, genebolic patterns most frequently found in hypertensives:
transcription, RNA processing and transport, and mRNAimpaired glucose tolerance and hyperinsulinemia (dur-
stability, as well as during post-translational events.ing fasting and after a glucose challenge) associated with
The circulating IGF-I is synthesized primarily by thelipid disturbances (increased low-density lipoprotein
liver under the control of growth hormone (GH). Thecholesterol and triglycerides, and decreased high-density
interaction of GH with its hepatic receptor stimulateslipoprotein cholesterol). Interestingly, administration of
expression of the IGF-I gene and release of IGF-I pep-the angiotensin-converting enzyme (ACE) inhibitor lisi-
tide [6]. Serum concentrations of IGF-I usually parallelnopril was associated with regression of the left-ventricu-
24-hour mean serum concentrations of GH, and IGF-Ilar mass and lessening of the microalbuminuria in the
inhibits the secretion of GH by the pituitary. Many otherfirst patient and with a decrease of the plasma insulin
factors control blood IGF-I concentrations as welllevels in the second patient.
(Table 1).It is now accepted that humoral factors, that is, vaso-
Besides the liver, many other organs produce IGF-Iactive substances, hormones, growth factors, and cyto-
[7]. Growth hormone, parathyroid hormone, glucocorti-kines, participate directly in the development of end-
coids, and sex steroids regulate the local production oforgan damage and metabolic alterations that occur in
IGF-I. Sara and Hall have proposed that intact IGF-I,hypertension. Several recent findings have underscored
which is bound by IGF-binding proteins (IGFBPs), rep-the potential participation of insulin-like growth factor I
resents the endocrine form of IGF-I present in the circu-(IGF-I or somatomedin C) in the development of cardiac
lation [8]. Truncated IGF-I, which is present in tissuesand renal damage in patients with essential hypertension.
and which displays weak affinity of binding to IGFBPs,These findings include the ability of IGF-I to directly
represents the locally acting autocrine or paracrine formpromote cardiac growth [1] and glomerular alterations
[2] and its ability to regulate glucose metabolism [3]. of IGF-I. According to this model, a protease that trun-
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Table 1. Factors that control circulating insulin-like
growth factor-I concentrations
Factor Impact on circulating IGF-I
Main factors
GH Serum concentration of GH usually parallels
24-hour concentration of IGF-I
IGF-I IGF-I suppresses GH secretion by pituitary
and indirectly controls its own secretion
Demographic factors
Age Peak at adolescence
Gender Females exhibit concentrations 20% more
than males
Pregnancy IGF-I concentrations are highest during the
third trimester
Nutritional status Fasting causes 70% decline in IGF-I levels
in 10 days Fig. 1. Distribution of circulating insulin-like growth factor I (IGF-I)
Other hormonal factors among its different binding proteins (IGFBPs) and access to its target
Thyroxine IGF-I concentrations decrease in hypothy- tissues. Symbols are: (s) IGF-I; ( ) IGFBP-3; (m) ALS, ( ) IGFBP-
roidism 1. The interaction of IGF-I with its receptor (IGF-IR) leads to several
Prolactin In the absence of GH, prolactin is a weak biologic effects, including glucose uptake and cell growth, differentia-
stimulus of IGF-I secretion tion, and survival.
Estrogens Physiologic estrogen replacement causes an
increase in IGF-I concentrations
a GH, growth hormone; IGF-I, insulin-like growth factor I
Mohan et al recently proposed that IGFBPs also mediate
IGF-independent biologic effects [11]. For example,
IGFBP-1 stimulates vascular smooth muscle cell (SMC)
cates the amino terminus of IGF-I regulates the produc- migration in an IGF-independent manner involving
tion of endocrine or autocrine-paracrine IGF-I [8]. binding to integrin receptors [12].
Approximately 99% of the circulating IGF-I is bound The IGF-I receptor (IGF-IR) is a heterotetrameric
to one of six IGFBPs [9]. The six IGFBPs characterized glycoprotein composed of two ligand-binding a-subunits
to date comprise a structurally related family of secreted of 706 amino acids and two transmembrane b-subunits
proteins that bind IGF-I with high affinity. The IGFBPs of 627 residues [13]. The human protein is produced by
vary in length from 216 to 289 amino acids and are mRNAs derived from a single 21-exon IGF-IR gene
composed of shared, cysteine-rich amino- and carboxy- located on chromosome 15q25-q26. The a-subunit con-
terminal domains. In contrast, the central portion of each tains the ligand-binding region of the receptor. The
IGFBP is unique. Each of the IGFBPs exhibits its own IGF-IR binds IGF-I with a dissociation constant (Kd)
characteristic pattern of expression in different tissues of less than 1 nm in intact cells; IGF-II binds with several-
and has a unique pattern of hormonal and developmental fold lower affinity, and insulin with more than 100-fold
regulation. lower affinity [14]. In general, biologic potency parallels
The IGFBPs are modulators of IGF-I’s action [10]. binding affinity. The b-subunit is composed of a short
The IGF-I present in the blood and other biologic fluids extracellular domain, a membrane-spanning segment,
is bound to IGFBPs, and this interaction maintains reser- and a large intracytoplasmic region containing a tyrosine
voirs of this growth factor in the circulation and else- kinase domain and sites of tyrosine and serine phosphor-
where. In conjunction with another circulating protein ylation [14].
termed the acid labile subunit (ALS), IGFBP-3 is primar- Stimulation of IGF-IR by ligand binding activates the
ily responsible for maintaining IGF-I levels in the blood intracellular tyrosine kinase and leads to rapid tyrosine
(Fig. 1). Other IGFBPs found in the bloodstream, includ- phosphorylation of insulin receptor substrate and to in-
ing IGFBP-1, IGFBP-2, and IGFBP-4, can cross endo- tracytoplasmic assembly of a complex consisting of a
thelial barriers and thus might transport IGF-I from the variety of proteins that are responsible for stimulation
circulation to peripheral tissues (Fig. 1). Several IGFBPs of diverse downstream signal transduction pathways [14].
are found in the extracellular environments of many These events then induce several biologic actions, includ-
tissues and might regulate IGF-I accessibility to recep- ing stimulation of hormone-sensitive glucose transport
tors and/or provide a local storage depot. These local [15] and activation of proteins involved in cell growth,
functions of IGFBPs could be modulated by interactions differentiation, and survival [16].
with the extracellular matrix and cell surface. In addition,
Actions of IGF-I potentially relevant to thelocal levels of several IGFBPs are modified through spe-
pathophysiology of hypertensioncific proteolysis. Thus, the dynamic interactions between
IGF-I and its binding proteins regulate the bioavailability The GH/IGF-I axis is primarily involved in the regula-
tion of somatic growth, but it also participates in theand, ultimately, the action of the growth factor. Finally,
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Table 2. Actions of insulin-like growth factor I of potential Insulin-like growth factor I mRNA expression is in-
relevance to the pathophysiology of cardiovascular diseases
creased in the myocardium of both pressure- [21] and
Site of action Action and potential consequence volume-overloaded [22, 23] animals and rats with sponta-
Heart neous hypertension (SHR) [24]. Furthermore, increased
Myocytes Induction of hypertrophy and promotion cardiac expression of IGF-I and its receptor also might
of cell survival that might contribute to
be required to produce the hypertrophic response ofdevelopment of LVHa
Vasculature the heart to the increased arterial load associated with
Endothelial cells Stimulation of NO production that might systemic hypertension [25].
participate in regulation of BP and re-
In addition, various observations suggest that IGF-Igional blood flow
Smooth muscle cells Stimulation of NO production that might functions as a survival factor by preventing the pro-
participate in regulation of BP and re- grammed cell death of many cell types [16], including
gional blood flow
cardiac myocytes [26]. Insulin-like growth factor I–Stimulation of growth that might contrib-
ute to remodeling of the vascular wall mediated inhibition of apoptosis is associated with in-
Kidney creased expression of a member of the anti-apoptosis
Vascular cells Stimulation of NO production that might
family of Bcl-2 proteins [27]. Interestingly, Bcl-2 expres-determine preglomerular vasodilation
and increase of GFR sion is increased over normal in several cell types in the
Mesangial cells Stimulation of NO production that might hypertrophied left ventricle of adult SHR rats [28, 29];
determine mesangial relaxation and in-
this model exhibits increased apoptosis of left-ventricularcrease of Kf
Stimulation of extracellular matrix protein cardiac myocytes [30]. Thus, the possibility exists that
synthesis that might promote glomeru- IGF-I helps maintain myocardial cell survival in hyper-
lar sclerosis
tensive cardiac hypertrophy via stimulation of the Bcl-Tubular cells Activation of Na1 channels that can facili-
tate distal Na1 and fluid reabsorption? 2 family of proteins.
Other In vitro [31] and in vivo [32] data have established
Skeletal muscle cells Stimulation of glucose uptake via IGF-
that IGF-I is a smooth muscle cell (SMC) mitogen. InIR that leads to diminished secretion of
insulin and lowers insulinemia addition, a number of findings suggest that IGF-I medi-
Fibroblasts Stimulation of fibrillar collagen synthesis ates the SMC growth response to different mechanical
that might facilitate organ and tissue fi-
and humoral stimuli. Increased SMC IGF-I expression,brosis
at both the mRNA and protein levels, is associated witha LVH, left-ventricular hypertrophy; NO, nitric oxid; BP, blood pressure; GFR,
glomerular filtration rate; Kf, ultrafiltration coefficient; IGF-IR, insulin-like the development of SMC hypertrophy and hyperplasia
growth factor I receptor during elevation in vascular wall stress [33, 34]. Nonhe-
modynamic factors that stimulate SMC growth, including
growth factors such as platelet-derived growth factor
[35], vasoactive substances such as angiotensin II [36],control of a number of physiologic processes, including
the regulation of glucose metabolism. Traditionally, in- and reactive oxygen species [37], also induce IGF-I ex-
pression in these cells. Thus, IGF-I may be an importantterest in the relationship between the GH/IGF-I axis and
the cardiovascular system has stemmed from the clinical link in mediating structurally adaptive growth responses
in the blood vessel wall.and epidemiologic observations that patients with acro-
megaly and stimulation of the GH/IGF-I axis have an In rats, administration of IGF-I decreases blood pres-
sure, a response mediated by nitric oxide (NO) [38]. Inincreased propensity to develop cardiovascular compli-
cations [17]. vitro experiments have confirmed that NO is an impor-
tant mediator of IGF-I–induced vascular relaxation [39].In the past few years, remarkable advancements have
been made in our understanding of the cellular and mo- In cultured endothelial cells, IGF-I stimulates endothe-
lial NO synthase (eNOS)–mediated NO production [40].lecular mechanisms involved in IGF-I’s action, including
its effects on cardiac, vascular, and renal tissues and In addition, Walsh and colleagues have shown that IGF-I
stimulates inducible NO synthase (iNOS)–mediated NOthe wide distribution of its receptors in these tissues
(Table 2). Solid evidence now implicates IGF-I in patho- production in cultured SMCs [41]. Therefore, IGF-I
might play a role in the regulation of blood pressure andphysiologic events related to arterial hypertension. Thus,
the question is how this interaction is mediated and what regional blood flow via NO.
Transgenic mice overexpressing GH also have ele-specific role IGF-I plays in relation to other regulators.
Several lines of evidence strongly suggest that IGF-I vated IGF-I levels. In these animals, glomerular enlarge-
ment and sclerosis develop as the result of increasedparticipates in the development of cardiac hypertrophy.
Insulin-like growth factor I induces hypertrophy of cul- glomerular production of extracellular matrix proteins
[42, 43]. However, mice transgenic for IGF-I also havetured ventricular myocytes [18, 19]. Increased cardiac
weight has been observed in mice transgenic for human increased glomerular size but do not develop accelerated
glomerular sclerosis, even though serum IGF-I levels inIGF-I with increased circulating levels of the factor [20].
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Table 3. Levels of insulin-like growth factor I (IGF-I) and growthIGF-I transgenic mice also were increased, as in GH
hormone (GH) in normotensive control subjects and
transgenic animals [42, 43]. This discrepancy is difficult hypertensive patients
to explain because glomeruli do not express GH recep-
Controls Hypertensives Lower limittors and might not synthesize IGF-I in vivo. Thus, GH- Parameter (N530) (N547) in acromegaly
induced effects on the glomerulus could only be ex-
IGF-I (ng/ml) 119 (88–155) 192 (100–287)a 400
plained by an indirect action by which GH increases GH (lg/liter) 0.35 (0.22–1.05) 0.83 (0.56–1.49)b 2
systemic IGF-I, which then acts through glomerular a P , 0.01, versus controls. Values are given as means and range
b P , 0.05, versus controlsIGF-IR [2]. This hypothesis is supported by the observa-
tion that IGF-I stimulates mRNA and secreted protein
levels of different extracellular matrix proteins in cul-
tured rat glomerular mesangial cells [44].
IGF-I. Fibroblasts are both a source of IGF-I and aStudies performed in humans [45, 46] and animals [47,
target for this growth factor. Insulin-like growth factor I48] have shown that exogenous and endogenous IGF-I
stimulates fibroblast proliferation and increases synthesisraises renal plasma flow and glomerular filtration rate
of fibrillar collagen types I and III [59]. Accordingly,(GFR) but produces inconsistent effects on tubular so-
biochemical evidence of increased synthesis of fibrillardium handling [2]. The renal hemodynamic actions of
collagen has been found in acromegalic patients withIGF-I seem to be secondary to a reduction in the renal
increased circulating levels of IGF-I [60]. Furthermore,efferent, and possibly afferent, arteriolar resistance [48]
synthesis of fibrillar collagen returns to normal in acro-and might be mediated by local induction and release
megalic patients treated with octreotide, a drug that nor-of NO [49]. In addition, IGF-I administration is accompa-
malizes IGF-I levels by reducing GH secretion [61].nied by an increase in the glomerular ultrafiltration coef-
A substantial increase in fibrillar collagen has beenficient [48]. Although this effect can be due to the relax-
observed in the cardiac ventricles and the arterial wallation of the mesangium [50], the possibility also exists that
of animals and humans with arterial hypertension [62,IGF-I increases glomerular capillary permeability [2].
63]. This fibrosis is the result of both increased collagenMany observations indicate that altered regulation of
types I and III synthesis by fibroblasts and unchangedglomerular hemodynamics plays a critical role in the
or decreased extracellular collagen degradation [64]. Be-pathophysiology of hypertension [51]. Moreover, glo-
sides hemodynamic factors, nonhemodynamic factors,merulosclerosis is one of the most relevant features of
that is, growth factors and vasoactive substances, can beclinical hypertension [52]. Thus, IGF-I emerges as a po-
involved in the disequilibrium between collagen synthe-tential candidate responsible for those renal alterations
sis and degradation that occurs in hypertension [65].in hypertension.
Thus, an excess of IGF-I also might promote the exagger-Several studies have demonstrated that IGF-I reduces
ated synthesis of fibrillar collagen in hypertensive pa-blood glucose and serum insulin concentrations in pa-
tients as in acromegalic patients.tients with insulin resistance [see Ref. 3 for review]. How
IGF-I works in patients with insulin resistance remains
Role of IGF-I in human hypertensionunclear, but the response to IGF-I in patients with muta-
Quantitative alterations of the GH/IGF-I/IGFBP axis.tions in the insulin-receptor gene or post-receptor defects
Circulating levels of IGF-I are increased in patients withsupports the notion that IGF-I acts through mechanisms
essential hypertension compared with those in normo-similar to, but distinct from, those of insulin itself, possi-
tensive subjects (Table 3) [66, 67]. Although abnormallybly exclusively through the IGF-IR [53, 54]. In addition,
high compared to normals, the levels of IGF-I in hyper-when IGF-I inhibits the secretion and lowers serum and
tensives are well below the established lower limit intissue concentrations of insulin [55], peripheral tissues
patients with active acromegaly [68].can upregulate their insulin receptors and become more
As I said previously, the liver is the major source ofresponsive to insulin. On the other hand, IGF-I inhibits
circulating IGF-I, its hepatic synthesis being under thethe secretion of glucagon, normally a powerful stimulus
control of GH [6]. Although they were abnormally highto hepatic glucose production [56].
[66], the GH levels of the hypertensive patients wereThe existence of glucose intolerance and hyperinsulin-
well below values found under conditions of GH hyper-emia in almost one-half of the hypertensive population
secretion (Table 3) [69]. Several other factors also mighthas established that resistance to insulin-stimulated glu-
influence circulating IGF-I levels (Table 1), namely, age,cose uptake is present in these individuals [57, 58].
estrogen levels, and nutritional status, but no differencesWhether stimulation of glucose uptake by IGF-I com-
in these parameters were found between hypertensivespensates for the defect or defects that block the action
with increased IGF-I and normotensives. Nevertheless,of insulin in hypertensives without insulin resistance re-
the increased secretion of GH does reflect the loss ofmains an interesting possibility.
Extracellular matrix metabolism is also affected by IGF-I–mediated inhibition of feedback in hypertensives.
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Table 4. Factors that regulate the production of insulin-like
growth factor I binding protein 1
Effect Factor
Stimulation Major influence
Glucagon
Cortisol
IGF-Ia
Minor influence
Calorie restriction
Hyperestrogenemia
Tumor necrosis factor-a
Catecholamines
LDL-cholesterol?
Inhibition Major influence
Insulin
Growth hormone
Minor influence
Aging
a IGF-I, insulin-like growth factor I; LDL, low-density lipoproteins
Fig. 2. Calculated index of tissue bioavailability of circulating insulin-
like growth factor I (IGF-I) in normotensive subjects (h), hypertensive
patients with normal levels of IGF-I-binding protein 1 (IGFBP-1) ( ),
and hypertensive patients with high levels of IGFBP-1 ( ). Values are and uterine decidua [72]. Results from studies in vitro and
expressed as mean 6 sem. (Modified from Laviades et al [71] with in vivo indicate that several factors regulate IGFBP-1
permission.)
production in these tissues (Table 4) [72]. The available
data indicate that the observed changes in the IGFBP-1
level in hypertensive patients cannot be attributed either
to an excess of cortisol, glucagon, and IGF-I or to aTherefore, the regulation of the GH/IGF-I axis in pa-
deficit of insulin and GH. In fact, although the levels oftients with essential hypertension is abnormal.
IGFBP-1 in serum appear to be related inversely to theWe reported that the ratio of IGFBP-3 and IGFBP-1
prevalent insulin levels, the mean levels of insulin wereis altered in the serum of patients with essential hyper-
normal in hypertensive patients with high IGFBP-1 lev-tension [70]. However, because these binding proteins
els. Similarly, glucagon and cortisol levels in these pa-were examined by Western ligand blotting, quantitative
tients also were within normal limits. In addition, GHinterpretation of this qualitative or, at best, semiquanti-
and IGF-I levels were increased similarly in members oftative method could not be performed. Thus, in a further
the two subgroups of hypertensive patients, those withstudy we analyzed the serum concentrations of these two
normal IGFBP-1 levels and those with high IGFBP-1IGFBPs by specific radioimmunoassay [71]. Whereas the
levels. Further studies are necessary to elucidate theconcentration of IGFBP-3 was not changed, the concen-
role of other potential mechanisms, for example, down-tration of IGFBP-1 in hypertensive patients was increased
regulation and inhibition of protein kinase C pathwaycompared with that in normotensive controls. An abnor-
[72], in the increase in serum levels of IGFBP-1 in themally high concentration of IGFBP-1 was actually ob-
approximately one-half of patients with essential hyper-served in 53% of hypertensives. The remaining 47% of
tension.the hypertensive patients did not exhibit this alteration
Pathophysiologic aspects. As I previously noted,in the IGFBP-1 level. We also determined an indirect
IGF-I stimulates production of NO both by endothelialindex of the tissue bioavailability of circulating IGF-I by
cells [40] and SMC [41]. Accordingly, IGF-I might playcalculating in each subject the ratio IGF-I 3 IGFBP-1:
a role in the control of blood pressure via NO. DataIGFBP-3. As Figure 2 shows, this index was significantly
suggest that the ability of IGF-I to modulate the vascularincreased in hypertensives with high IGFBP-1 as com-
NO system is decreased in some patients with essentialpared to normotensives and hypertensives with normal
hypertension [73].IGFBP-1. Therefore, patients with high IGFBP-1 levels
On the other hand, Vecchione et al recently reportedwere considered hypertensive with an abnormally in-
that IGF-I sensitization of endothelial a2-adrenergic aor-creased access to tissues of the circulating IGF-I. Patients
tic vasorelaxation is impaired in SHR as compared towith normal IGFBP-I levels were termed hypertensive
normotensive Wistar-Kyoto (WKY) rats [74]. Thesewith normal access to tissues of the factor.
findings suggest that the endothelium-dependent vasore-What causes the abnormally high serum level of
laxant actions of IGF-I can be reduced in rats and hu-IGFBP-1 found in approximately one-half of patients
with essential hypertension? Both IGFBP-1 mRNA and mans with genetic hypertension. Accordingly, a dimin-
ished ability of IGF-I to reduce blood pressure inprotein expression have been identified in human liver
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Fig. 4. Clearance of creatinine and urinary excretion of albumin in
hypertensive patients with normal levels of insulin-like growth factorFig. 3. Mean arterial pressure and left-ventricular mass index in hyper-
I-binding protein 1 (IGFBP-1) ( ) and hypertensive patients with hightensive patients with normal levels of insulin-like growth factor I-binding
levels of IGFBP-1 ( ). Values are expressed as mean 6 sem. (Modifiedprotein 1 (IGFBP-1) ( ) and hypertensive patients with high levels of
from Laviades et al [71] with permission.)IGFBP-1 ( ). Values are expressed as mean 6 sem. (Modified from
Laviades et al [71] with permission.)
sive animals and healthy humans [45–48]. This effect has
hypertensive patients might be a factor contributing to been attributed to changes in glomerular hemodynamics
hypertension. mediated by NO. However, Inishi and colleagues re-
High IGF-I levels are associated with LVH in patients ported recently that modulation of glomerular hemody-
with essential hypertension [66, 67, 75, 76]. Furthermore, namics by the factor is absent in SHR [82]. This finding
compared with hypertensives with normal access to tis- accords with the observation that the ability of IGF-I to
sues of IGF-I, hypertensives with increased access to stimulate vascular NO is impaired in essential hyperten-
tissues of the factor exhibited an increased left-ventricu- sion [73]. Thus, it is unclear whether hyperfiltration ob-
lar mass despite similar levels of blood pressure (Fig. 3) served in hypertensives with increased tissue access of
[71]. Therefore, cardiac hypertrophy in these patients circulating IGF-I can result from an increased interaction
might result in part from the increased interaction of of the factor with its receptors located in glomerular
IGF-I with its cardiac receptors. In support of this possi- arterioles.
bility is the finding that IGFBP-1 transgenic mice with Several potential mechanisms have been proposed to
abnormally high serum concentrations of the protein explain the presence of increased urinary albumin excre-
product had a relative gain in heart weight [77]. tion in patients with essential hypertension. Increased
Andronico et al have demonstrated that circulating urinary albumin excretion in hypertension likely is a
levels of IGF-I increase in hypertensive subjects follow- consequence of increased permeability of the glomerular
ing a standard hemodynamic load (that is, standing) pro- filter, but other factors might be involved, such as the
portional to the increase in pressure load, measured as development of glomerular sclerosis [83]. As I previously
cardiac rate 3 blood pressure product [78]. Furthermore, mentioned, IGF-I might enhance glomerular capillary
they found a positive correlation between circulating permeability [29]. In addition, IGF-I induces higher
IGF-I and the activity of Na1/Li1 countertransport in growth response and protein synthesis in mesangial cells
patients with essential hypertension [67]. Interestingly, from SHR than in mesangial cells from WKY [84].
Weder and coworkers have shown that Na1/Li1 count- An altered IGF-I level can contribute to metabolic
ertransport correlates positively with pressure stress on derangements in hypertensive patients. Hypertensives
the vascular system [79]. Therefore, one can hypothesize with high IGFBP-1 exhibit lower glucose, triglyceride,
that hemodynamic injury of the vascular wall facilitates and insulin levels than do hypertensives with normal
the release of local IGF-I into the bloodstream in hyper- IGFBP-1 (Fig. 5) [71]. In addition, compared with hy-
tensive patients. If this is so, the increased circulating pertensives with normal IGFBP-1, patients with high
levels of IGF-I in hypertensives could be interpreted IGFBP-1 showed a decreased insulin:glucose ratio and
also as a marker of vascular hypertensive damage. decreased glucagon levels (Fig. 5) [71]. Thus, increased
We have reported an association between increased access to tissues of IGF-I could improve glucose metabo-
IGF-I levels and altered renal hemodynamics and func- lism in essential hypertension, a condition linked to insu-
tion in hypertensive patients [80, 81]. We also found that lin resistance [57, 58].
hypertensives with increased tissue access of circulating Our group recently confirmed this possibility [85]. We
IGF-I had glomerular hyperfiltration and increased mi- estimated both insulin resistance and b-cell function in
croalbuminuria as compared with hypertensives with patients with essential hypertension using the homeosta-
normal tissue access of the factor (Fig. 4) [71]. sis model assessment [86]. Whereas hypertensives with
high IGFBP-1 exhibited normal values of insulin resis-As previously noted, IGF-I raises GFR in normoten-
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cantly in diabetic patients chronically treated with capto-
pril [94]. The likelihood that ACE inhibitors diminish
circulating IGF-I by suppressing the angiotensin II-
dependent stimulus for GH production has been con-
firmed by the finding that GH levels diminish in hyper-
tensive patients chronically treated with ACE inhibitors
[75, 76].
Another aspect of interest is that the response of LVH
and extracellular matrix metabolism to ACE inhibitors
is related to their ability to normalize IGF-I. In fact,Fig. 5. Plasma insulin levels and insulin:glucose ratio in hypertensive
LVH regressed in hypertensive patients in whom thepatients with normal levels of insulin-like growth factor I-binding pro-
tein 1 (IGFBP-1) ( ) and hypertensive patients with high levels of circulating levels of IGF-I were normalized after treat-
IGFBP-1 ( ). Values are expressed as mean 6 sem. (Modified from ment with ACE inhibitors but persisted in those in whomLaviades et al [71] with permission.)
IGF-I levels remained abnormally high after treatment,
irrespective of the impact of therapy on blood pressure
[75, 76]. Similarly, serum concentrations of PIIIP became
normal in hypertensive patients in whom IGF-I levelstance and b-cell function, hypertensives with normal
IGFBP-1 exhibited abnormally high values of both these decreased to normal values after treatment with lisinopril
but remained abnormally high in hypertensives exhibit-parameters. Furthermore, we noted an inverse correla-
tion between IGFBP-1 and insulin resistance in the ing increased IGF-I levels after treatment, independently
of the response of blood pressure to ACE inhibition [87].whole group of hypertensives. It therefore appears that
increased tissue access of IGF-I counteracts the abnor- These data support the notion that ACE inhibition af-
fects left-ventricular mass and fibrillar collagen metabo-mal interaction of insulin with its target tissues in essen-
tial hypertension. lism in hypertension through inhibition of the production
of circulating IGF-I.We also noted an association between increased serum
concentrations of IGF-I and increased serum concentra- Finally, we recently observed that long-term adminis-
tration of lisinopril increases serum levels of IGFBP-1tions of procollagen type-III amino-terminal peptide
(PIIIP) in patients with essential hypertension [87]. Fi- and normalizes glucose-related parameters in patients
with essential hypertension and insulin resistance atbrillar collagen type III is synthesized as a large precursor
protein, procollagen type III, which has additional pro- baseline [85]. Albeit preliminary, these findings reinforce
the notion that tissue access of IGF-I might be one oftein sequences (pro-peptides) at its amino-terminal and
carboxy-terminal ends. Largely cleaved from the pro- the important factors regulating insulin sensitivity in es-
sential hypertension. Further studies are necessary tocollagen molecules before these are assembled into fi-
bers, PIIIP then is released into the blood. Serum con- confirm whether the improvement of insulin sensitivity
reported in hypertensive patients treated with ACE in-centrations of PIIIP therefore could reflect the rate of
synthesis of new collagen type III [88]. We believe that hibitors involves changes at the GH/IGF-I/IGFBP axis
level.the finding that serum PIIIP is increased in patients with
essential hypertension indicates that fibrogenic hyperac-
Conclusiontivity is present in these patients [89]. Thus, the possibil-
ity exists that an excess of IGF-I is involved in excess In this Nephrology Forum, I have updated recent evi-
dence strongly suggesting that alterations in the produc-organ and tissue fibrogenesis in patients with essential
hypertension. tion and distribution of circulating IGF-I play a role in
some pathophysiologic features of essential hypertensionACE inhibition and the GH/IGF-I/IGFBP axis. We
previously demonstrated that the ACE inhibitor capto- (Fig. 6). The liver overproduces IGF-I and IGFBP-1
under the influence of GH and unknown factors, respec-pril, but not the b-blocker bisoprolol, decreases circulat-
ing IGF-I levels in patients with essential hypertension tively. The hemodynamic loading imposed by hyperten-
sion on the vascular wall also might facilitate the local[75]. We later showed that different ACE inhibitors can
reduce circulating IGF-I levels irrespective of their synthesis and secretion of IGF-I. However, the lack of
response of the endothelium to IGF-I can be responsiblechemical structures [76]. Several observations help ex-
plain the influence of ACE inhibition on IGF-I levels. for a lack of vasorelaxant effect of the factor. An excess
of circulating IGF-I coupled with an exaggerated accessIn vitro and in vivo studies suggest that angiotensin II
stimulates pituitary GH release both in humans and ani- to its target tissues can contribute to the development
of LVH and an increase in albuminuria. On the othermals [90–92]. Humans acutely treated with enalapril tend
to have diminished GH responses to insulin-induced hy- hand, increased tissue availability of IGF-I might stimu-
late glucose transport by the cells, and this in turn pre-poglycemia [93]. Urinary levels of GH decrease signifi-
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Fig. 6. Potential involvement of insulin-like
growth factor I (IGF-I) in some pathophysio-
logic features of essential hypertension. In-
creased tissue availability of circulating IGF-I
might facilitate the elevation of peripheral re-
sistance and contribute to the development of
cardiac and renal damage. On the other hand,
it could stimulate the peripheral metabolism
of glucose.
vents pancreatic hypersecretion of insulin and the meta- excretion. On the other hand, an increase in both left-
bolic abnormalities linked to insulin resistance. In view ventricular IGF-I mRNA and protein has been described
of the complexity of the GH/IGF-I/IGFBP axis, we still in experimental models of high- (two-kidney, one-clip
need answers to many questions before we will under- Goldblatt hypertension), moderate- (uninephrectom-
stand the exact role of the axis in the development of ized SHR), and low-renin (DOCA salt rats) hyperten-
the end-organ damage and the metabolic disturbances sion [21–23]. The consistency of the IGF-I findings in
associated with hypertension. The potential impact on these three models suggests that they occur indepen-
the GH-IGF axis of antihypertensive drugs with well- dently of the systemic renin-angiotensin endocrine system.
described end-organ protective and metabolically favor- Nonetheless, a number of in vitro findings suggest that
able actions (such as ACE inhibitors) opens an interest- angiotensin II interacts with IGF-I at several levels in
ing new dimension in the therapy of arterial hyperten- SMCs. Exposure of SMCs to angiotensin II markedly
sion. No doubt, information on this topic will increase increases IGF-I mRNA [36]. Angiotensin II stimulates
in the near future, and a better understanding of the IGF-IR gene transcription by a protein kinase C–inde-
precise role of IGF-I in hypertension will enhance our pendent pathway [95]. Furthermore, angiotensin II in-
ability to assess and treat hypertensive patients. duces rapid tyrosine phosphorylation of IGF-IR sub-
strate-1 [96]. Interestingly, the angiotensin II-induced
increase in DNA synthesis is almost completely abol-QUESTIONS AND ANSWERS
ished when SMCs are coincubated with an anti–IGF-IDr. Nicolaos E. Madias (Chief, Division of Nephrol-
antibody [36]. Angiotensin II thus stimulates transcrip-ogy, New England Medical Center, Boston, Massachu-
tion of the IGF-I and IGF-IR genes in SMC, and thesetts, USA): In addition to a subpopulation of patients
interaction of IGF-I with its receptor is required forwith essential hypertension, do patients with secondary
angiotensin II-induced DNA synthesis in these cells. Thishypertension also manifest elevated serum IGF-I levels?
interaction might have particular relevance to our under-Does the level of plasma renin activity influence the level
standing of the synergistic action of angiotensin II andof IGF-I whether in experimental or clinical hyperten-
IGF-I for promoting SMC proliferation in vivo [97].sion?
Dr. Madias: How strong is the evidence that the serumDr. Di´ez: Acromegalic patients with hypertension
IGFBP-1 determines the tissue accessibility of the fac-also exhibit increased serum levels of IGF-I [17]. No
tor? After all, altered concentrations of the IGFBPsdata are available regarding serum levels of IGF-I in
might not necessarily imply altered distribution of IGF-Ipatients with other forms of secondary hypertension.
among them. Do you have information about the satura-With respect to your second question, there are no clini-
tion of these IGFBPs and their affinity for IGF-I incal data on serum levels of IGF-I in hypertensive patients
normotension versus hypertension?classified according to the level of plasma renin activity
as it relates to the concurrent rate of urinary sodium Dr. Di´ez: Several potential mechanisms for enhancing
Nephrology Forum: IGF-I in essential hypertension 753
IGF-I bioavailability in the target tissues have been pro- volved in the increased sensitivity of SHR mesangial
cells to the growth-promoting effect of IGF-I, that sameposed [98]: increase of the level of free IGF-I, increase
of the ratio of IGF-I to IGFBP-3, increase of the ratio mechanism may be involved in the pathogenesis of the
glomerular alterations seen in hypertension, that is, glo-of IGFBP-1 to IGFBP-3, increase of the rate of proteoly-
sis of IGFBP-3, decrease of the rate of proteolysis of merulosclerosis.
Dr. Madias: Just as is the case for IGF-I, about 50% ofIGFBP-1, and increase of IGF-IR abundance in the tar-
get tissues. Data presented today in hypertensive pa- patients with essential hypertension have an overactive
Na1/H1 exchanger in their blood cells. This phenotypetients are in agreement with the first three possibilities.
Thus, it is reasonable to hypothesize that increased se- is associated with a number of adverse cardiorenal mani-
festations. What do we know about the relationship be-rum levels of IGFBP-1 determine increased transport of
circulating IGF-I to its target cells in hypertensive pa- tween IGF-I and the Na1/H1 exchanger? Do patients
with high access to tissues of IGF-I also have an overac-tients with increased serum levels of IGF-I and normal
serum levels of IGFBP-3. Although we have not ana- tive Na1/H1 exchanger? Do mice transgenic for IGF-I
overexpress the Na1/H1 exchanger?lyzed changes in the saturation level or in the affinity of
IGFBPs for IGF-I, about 75% of IGF-I in the circulation Dr. Di´ez: Recently, Andronico et al reported a posi-
tive correlation between circulating IGF-I and the activ-is complexed with IGFBP-3, whereas almost all the re-
mainder of the circulating IGF-I is bound to lower molec- ity of erythrocyte Na1/Li1 countertransport in patients
with essential hypertension [67]. Hypertensives with in-ular-mass IGFBPs, namely IGFBP-1 [9]. On the other
hand, IGFBP-3 has a higher affinity for IGF-I than does creased Na1/Li1 countertransport activity have a worse
cardiovascular risk profile than do hypertensive patientsIGFBP-1 (2.1 and 6.5 nm, respectively) [99]. Thus, an
excess of IGFBP-1 might not be enough to modify the with normal Na1/Li1 countertransport [104]. Canessa
has proposed that Na1/Li1 countertransport representsdistribution of bound IGF-I in such a way that changes
in the tissue access of the factor result. However, findings a mode of functioning of the cell membrane Na1/H1
exchanger [105]. Increased Na1/Li1 countertransportby Hardouin et al in patients with different alterations
of the GH/IGF-I axis suggest that transport of circulating therefore could reflect an overactive Na1/H1 exchanger.
On the other hand, recent papers reported that IGF-IIGF-I to its target tissues parallels changes in the ratio
between serum IGFBP-1 and serum IGFBP-3, irrespec- stimulates Na1/H1 exchanger activity in SMCs [106,
107]. Since IGF-IR are present in erythrocytes, it istive of changes in the saturation and affinity of these
IGFBPs [100]. tempting to speculate that an excess of IGF-I results in
overactivity of the erythrocyte Na1/Li1 exchanger inDr. Jesu´s Egido (Associate Chief, Division of Ne-
phrology, Fundacio´n Jime´nez Dı´az, and Professor of hypertension. Nevertheless, since no data are available
on the expression of the Na1/Li1 exchanger in IGF-IMedicine, Auto´noma University, School of Medicine, Ma-
drid, Spain): Your data suggest that in vivo growth-pro- transgenic mice, that hypothesis remains to be tested.
Dr. Jose´ L. Rodicio (Chief, Division of Nephrology,moting effects of IGF-I are influenced by the level of
blood pressure. Does any experimental evidence support “12 de Octubre” University Hospital, and Professor of
Medicine, Complutense University, School of Medicine,this possibility?
Dr. Di´ez: Increased sensitivity to the growth-promot- Madrid): Your findings indicate that IGFBP-1 is involved
in insulin resistance in patients with essential hyperten-ing effects of specific growth factors, including IGF-I, has
been shown in SMCs from hypertensive animals [101]. sion. Do data support a glucoregulatory role for this
protein?Upregulation of IGF-IR is accompanied by increased
responsiveness of SMCs to IGF-I [102]. Interestingly, Dr. Di´ez: Possible evidence of the glucoregulatory
role of IGFBP-1 is seen in fasting healthy subjects follow-several growth factors and angiotensin II increase IGF-
IR in SMCs [102]. Together, these findings suggest that ing a single injection of recombinant human IGF-I, which
elicits a profound acute increase in serum IGFBP-1 lev-hypersensitivity to IGF-I mediates SMC hypertrophic
and hyperplastic responses to growth factors in arterial els, accompanied by a marked suppression of insulin
levels and a 20% decline in blood glucose [108]. The peakhypertension. On the other hand, Heidenreich et al have
shown that IGF-I induces higher growth response in IGFBP-1 response at six hours is strongly associated
with the peak glucose response at eight hours. Thusmesangial cells from SHR than in mesangial cells from
WKY rats [84]. These authors also demonstrated that the insulin-like activity of IGF-I, in conditions in which
insulin secretion is greatly suppressed, might be closelychanges of cytosolic free-calcium concentration were not
associated with increased responsiveness of SHR mesan- regulated by IGFBP-1 [108].
Dr. Rodicio: You found that serum levels of IGFBP-1gial cells to IGF-I [84]. In this regard, it is possible that
the tyrosine kinase activity of growth factors is crucial are inversely related to insulin resistance in patients with
essential hypertension. Do you know other clinical con-for mesangial cell mitogenicity rather than effects on
cytoplasmic calcium [103]. Whatever the mechanism in- ditions in which a similar association has been found?
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Dr. Di´ez: Polycystic ovary syndrome also is character- eNOS-mediated NO production by endothelial cells.
Could you elaborate on the molecular mechanisms in-ized by insulin resistance. Morris and Falcone found
that serum IGFBP-1 concentrations related positively to volved in such an effect? Can IGF-I also regulate the
inducible form of NOS?insulin sensitivity (r 5 0.76, P , 0.003, N 5 15) in this
condition [109]. Furthermore, IGFBP-1 concentration Dr. Di´ez: In fact, stimulation with IGF resulted in a
rapid, dose-dependent increase in NO in cultured humanremained a significant predictor of insulin sensitivity
when controlled for the body mass index in these women. umbilical vein endothelial cells and cultured immortal-
ized rat renal interlobar artery endothelial cells [40]. TheDr. Fernando Valderra´bano (Chief, Department of
Nephrology, Gregorio Maran˜o´n University Hospital, and effect of IGF-I was suppressed by pretreatment with
anti-IGF-I antibody, suggesting that it was specific forProfessor of Medicine, Complutense University School
of Medicine): You have proposed a role for IGF-I in IGF-I. An inhibitor of NO synthesis, NG-nitro-l-arginine
methyl ester significantly blunted the responses to IGF-I,insulin resistance associated with essential hypertension.
Do you think this situation obtains in patients with but dexamethasone preincubation did not reduce the
IGF-I–induced release of NO. These results indicate thatchronic renal failure?
Dr. Di´ez: The IGF-I/IGFBP axis has been character- the observed IGF-I–induced release of NO is a result of
activation of the constitutive, rather than the inducible,ized in patients with chronic renal failure [see Ref. 2].
Most investigators found normal serum IGF-I and in- type of eNOS. Genistein, a tyrosine kinase inhibitor, pro-
foundly suppressed the IGF-I–induced release of NO, butcreased serum IGFBP-1 and -3 levels in patients with
chronic renal failure. On the other hand, we have long IGF-I did not affect the cytosolic concentration of cal-
cium in either type of cells. Therefore, IGF-I–inducedknown that patients with chronic renal failure are resis-
tant to the effects of IGF-I on protein anabolism [110]. NO production by both types of endothelial cells is medi-
ated via a tyrosine kinase–dependent mechanism. Dis-Studies carried out by Ding and associates strongly sug-
gest that the IGF-I resistance in chronic renal failure is crepant data have been reported concerning the poten-
tial effects of IGF-I on the inducible form of NOS. Schinicaused, at least in part, by an IGF-I post-receptor defect
[111]. However, Mak recently reported that the ability et al found that IGF-I inhibits cytokine-mediated induc-
tion of NOS expression and activity in SMCs [114]. Inof IGF-I infusion to stimulate total-body glucose uptake
is maintained in rats with chronic renal failure that are contrast, Walsh et al reported that IGF-I stimulates in-
ducible NOS-mediated NO production in SMCs [115].insulin resistant [112]. It is therefore unclear how changes
in tissue accessibility and actions of IGF-I participate in Since methods used in the two studies were different,
further studies are necessary to clarify the real impactthe multifactorial origin of insulin resistance in chronic
renal failure. of IGF-I on inducible NOS.
Dr. Egido: A number of in vitro studies have shownDr. Egido: From your findings, it appears that treat-
ment with an ACE inhibitor increases the serum level of that IGF-I inhibits apoptosis. Have you any information
on the ability of IGF-I to block apoptosis in vivo?IGFBP-1. Do you have any information on the potential
ability of angiotensin II to regulate IGFBP synthesis? Dr. Di´ez: Resnicoff and colleagues showed that IGF-I
protects cells from apoptosis in transplanted tumorsDr. Di´ez: In fact, we recently observed that chronic
administration of the ACE inhibitor lisinopril is as- [116]. Moreover, its administration attenuates cardiomy-
ocyte death in ischemic reperfusion injury [26]. A recentsociated with a significant increase in serum levels of
IGFBP-1 in patients with essential hypertension [85]. report showed that overexpression of human IGF-I in
transgenic mice protects from cardiomyocyte apoptosisThis effect appears to be independent of the hemody-
namic effect of the drug. Thus, the increase might be after infarction [117]. The mechanisms by which IGF-I
prevents apoptosis are unknown, but the IGF-I/IGF-IRrelated to the ACE inhibition. Whereas angiotensin II
infusion reduces serum IGFBP-3 levels and increases system mediates the formation of some molecules that
inhibit apoptosis (that is, Bcl-2 oncoproteins) [27]. Inserum IGFBP-2 levels in rats, no changes have been
observed in the serum levels of other IGFBPs, including addition, IGF-I blocks the activation of some members
of the interleukin-converting-enzyme family that act asIGFBP-1 [113]. The possibility therefore exists that
changes in serum IGFBP-1 levels after lisinopril treat- an effector of apoptosis [118].
Dr. Rodicio: Would you comment on the effects ofment are unrelated to a reduced availability of angioten-
sin II but relate to changes in other active fragments of IGF-I on sodium homeostasis and tubular sodium han-
dling?angiotensin II—that is, angiotensin II (1–7), angiotensin
III, angiotensin IV—or increased availability of bradyki- Dr. Di´ez: Clinical studies suggest that pharmacologic
administration of IGF-I causes edema that is transientnin-related products.
Dr. Santiago Lamas (Senior Investigator, Center for in most normal subjects but which can be more severe
in individuals who have greater than usual salt or fluidBiological Research, High Council for Scientific Re-
search, Madrid): You mentioned that IGF-I stimulates intake [see Ref. 2]. Experimental studies in cultured A6
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cells suggest that IGF-I activates distal tubular apical vision of Nephrology, Fundacio´n Jime´nez Dı´az, Auto´-
noma University, School of Medicine, Madrid): Do youNa1 channels [119]. Such activation could account for
increased distal tubular sodium and fluid absorption. In have data on the existence of an alteration in the negative
feedback of IGF-I on GH secretion?our study, no differences in either net or fractional so-
dium excretion were observed between hypertensive pa- Dr. Di´ez: As I said, the association of increased GH
levels with exaggerated IGF-I levels in patients with es-tients with increased tissue access of circulating IGF-I
and hypertensive patients with normal tissue access of sential hypertension suggests loss of the physiologic sup-
pression of GH secretion by IGF-I [69]. Advancing agecirculating IGF-I [71]. It is important to note that all
these patients were studied under conditions of low- is associated with an apparent reduction in sensitivity to
the GH-suppressive effects of IGF-I [122]. However, nomoderate sodium intake (100–120 mmol/day).
Dr. Pietro Zucchelli (Professor, Malpighi Depart- differences in age were observed among hypertensive
patients with increased levels of GH, hypertensives withment of Nephrology, Policlinico S. Orsola-Malpighi, Bo-
logna, Italy): Could increased delivery of circulating normal levels of the hormone, and normotensive individ-
uals [69]. Studies looking at the GH-suppressive effectIGF-I to the tubulointerstitial space be involved in the
development of chronic renal disease in essential hyper- of recombinant human IGF-I infusion could be useful
to determine the sensitivity of GH secretion to IGF-Itension?
Dr. Di´ez: Mice transgenic for the human IGF-I gene negative feedback in hypertensive patients.
Dr. Ricardo Bosch (Professor, Department of Physi-display renal hypertrophy without sclerosis [42, 43]. In
contrast, excess of GH and IGF-I, as in transgenic mice ology, University of Alcala´ de Henares, School of Medi-
cine, Alcala´ de Henares, Spain): Are you aware of studiesexpressing the bovine GH gene [42, 43], favors the devel-
opment of renal sclerosis. Both GH and IGF-I may act looking at the urinary excretion of IGF-I in patients with
essential hypertension?synergistically for the development of experimental
nephrosclerosis. This is consistent with in vitro observa- Dr. Di´ez: To my knowledge, no studies have investi-
gated urinary levels of IGF-I in patients with essentialtions of a synergistic effect of these peptides on fibroblast
proliferation [120]. Interestingly, hypertensive patients hypertension. However, a recent report described sig-
nificantly increased urinary IGF-I levels in patients withwith increased tissue access of circulating IGF-I also
nondiabetic renal disease and chronic renal failure asexhibited elevated levels of GH [71]. Certainly, we can
compared to levels in patients with nondiabetic chronicspeculate that the interaction of GH and IGF-I facilitates
renal disease and normal renal function and in healthythe development of tubulointerstitial fibrosis in these
controls [123]. Urinary IGF-I did not correlate with se-patients.
rum IGF-I but demonstrated a significant negative corre-Dr. Jose´ M. Lopez-Novoa (Professor and Chairman,
lation with the clearance of creatinine in nondiabeticDepartment of Physiology, University of Salamanca,
patients [123]. These data in nondiabetic patients withSchool of Medicine, Salamanca, Spain): You have shown
renal disease suggest the possible participation of renalthat IGF-I infusion in humans and animals is associated
IGF-I in the progression of renal disease as a potentialwith an increase in GFR. However, this parameter was
“toxic” protein for tubular cells.only slightly increased in hypertensive patients with in-
Dr. Madias: Are there observations either in animalscreased tissue accessibility of the factor as compared
or humans on the effects of octreotide on the cardiovas-with hypertensive patients who had normal tissue acces-
cular system and the kidneys?sibility. How do you explain these findings?
Dr. Di´ez: Yes, increasing evidence supports a poten-Dr. Di´ez: Kurokawa’s group recently reported that
tial therapeutic role for the somatostatin analogue oc-IGF-I infusion, which increases GFR in normotensive
treotide in several cardiovascular and renal pathologicWKY rats, fails to induce the same effect in SHR [82].
conditions. For instance, suppression of GH productionThe mechanism underlying this discrepant renal re-
by octreotide in patients with acromegaly is associatedsponse is not known. It is possible that the ability of
with a significant regression of LVH and improvementIGF-I to induce NO-mediated renal vasodilation and
of cardiac function [17]. On the other hand, octreotideincrease GFR is impaired in hypertension [73]. On the
infusion into either patients with essential hypertensionother hand, IGF-I–induced attenuation of mesangial cell
[124] or hypertensive patients with type-II diabetes [125]contraction by vasoactive agents is diminished in cells
is accompanied by a significant decrease in plasma insulinfrom SHR as compared to cells from normotensive WKY
levels and an increased natriuretic response to a sodiumrats [121]. Therefore, renal SMCs and glomerular cells
load. Finally, in rats with streptozotocin-induced diabe-from hypertensive rats appear to be resistant to the relax-
tes, octreotide can prevent the development of structuralant effects of IGF-I. Whether this is also the case in
and functional renal damage [126].patients with essential hypertension and increased tissue
access of circulating IGF-I deserves further studies. Reprint requests to: Dr. J. Dı´ez, Unidad de Fisiopatologı´a Vascular,
Facultad de Medicina, C/Irunlarrea s/n, 31080 Pamplona, Spain.Dr. Carlos Caramelo (Consultant Nephrologist, Di-
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